Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

First two phase III trials for ferumoxytol commence

April 30, 2004

New PPARalpha/PPARgamma agonists prepared and tested at Roche

April 30, 2004

PARP activation shown to be involved in diabetic neuropathy in mice and rats

April 29, 2004

New indication and strength approved for Hectorol

April 29, 2004

GA-GCB enters clinical trial for Gaucher's disease

April 29, 2004

Selective antagonist action on food intake not only mediated by NPY Y5 receptor

April 29, 2004

Inhibition of dopamine transport: a novel treatment for obesity

April 29, 2004

Protein tyrosine phosphatase 1B inhibitors from Roche

April 29, 2004

Novo Nordisk claims the preparation and use of novel PPARdelta agonists

April 28, 2004

TAK-559, a PPARalpha/gamma coagonist for the treatment of dyslipidemia

April 28, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.